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Introduction:
Non-medical consumption of psychostimulants is a global phenomenon that places tremendous demands on fiscal and public health care systems (Degenhardt and Hall, 2012) . In addition to "classical" psychostimulants, like amphetamine and cocaine, the markets are now flooded with novel designer drugs that mimic the action of these "classical" scheduled substances (Baumann and Volkow, 2016) . These new psychoactive substances (NPS) are easy to obtain, often distributed via the Internet, and provide
powerful, yet (in many cases) legal alternatives to regulated cannabinoids, hallucinogens, opioids and stimulants (Meyer, 2016) . NPS are introduced into the markets at an alarming rate. For instance, 251 NPS were reported in 2012, outnumbering the controlled substances that year (i.e. 234 scheduled substances; World Drug Report, 2013 1 ). In 2014, stimulant-type drugs classified as synthetic cathinones and phenethylamines were the dominant NPS in the European Union (Tyrkko et al., 2016) , providing indirect evidence for the widespread abuse of psychostimulants.
Around 2010, NPS derived from the naturally occurring parental compound cathinone were marketed as legal replacements for the stimulants MDMA and cocaine.
Mephedrone and MDPV represent two major cathinone derivatives found in "bath salts" or "plant food" products (Ross et al., 2011 , Spiller et al., 2011 . Deleterious side effects were associated with "bath salt" intoxications (Lusthof et al., 2011 , Maskell et al., 2011 , Murray et al., 2012 , Spiller et al., 2011 and attracted media attention. Mephedrone and MDPV were classified as schedule I substances in 2011 (DEA, 2011) . However, these drugs continue to be abused in spite of the their illegal status (Styszko et al., 2016 , Hockenhull et al., 2016 , Archer et al., 2014 , Archer et al., 2013 . Stimulant-type "bath salts" elevate the extracellular concentration of monoamines. This is achieved by their ability to disrupt uptake mechanisms for dopamine, norepinephrine and serotonin.
Under physiological conditions, the high-affinity transporters for dopamine (i.e. dopamine transporter, DAT), serotonin (i.e. serotonin transporter, SERT) and norepinephrine (norepinephrine transporter, NET) sequester their respective substrates via a secondary-active transport process (Kristensen et al., 2011) and operate in an orchestrated manner with vesicular monoamine transporters (Egana et al., 2009) to replenish vesicular monoamine stores (Sitte and Freissmuth, 2015) . Earlier studies conclusively showed that mephedrone acts as a substrate-type releaser, promoting 1 https://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf
carrier-mediated reverse transport of monoamines via DAT, NET and SERT. On the contrary, the same laboratories showed that MDPV acts as a potent, non-transported inhibitor of DAT and NET, but was a less potent inhibitor of SERT (Baumann et al., 2012 , Simmler et al., 2013 . Interestingly, non-transported inhibitors interfere with the effects of substrate-type releasers. For instance, in the presence of cocaine, S(+)-amphetamine fails to induce both inwardly directed currents via DAT stably expressed in HEK293-EM4 cells (Erreger et al., 2008) and NET-mediated release from HEK293-cells stably expressing this transporter (Mayer et al., 2018) . Based on its pharmacological profile, these observations indicate that MDPV would counteract substrate-induced reverse transport in a cocaine-like fashion. It is paradoxical then, that co-existence of MDPV and amphetamine-like releasers has been detected in biological samples of a plethora of drug users (Kriikku et al., 2011) including in drug samples that were analyzed by massspectrometry by the Viennese drug prevention project "CheckiT ! Check your drugs" 2 ).
Recently, we reported that organic cation transporter 3 (OCT3) plays an unsuspected role in the actions of S(+)amphetamine (Mayer et al., 2018) . OCT3 is a promiscuous lowaffinity/high-capacity transporter that has been implicated in monoamine-homeostasis (Daws, 2009, Courousse and Gautron, 2015) . OCT3 is cocaine-insensitive (Amphoux et al., 2006) , is expressed in neurons (Vialou et al., 2008 , Gasser et al., 2016 , Mayer et al., 2018 , Kristufek et al., 2002 , and capable of bidirectional monoamine transport (Koepsell et al., 2007) . We found that amphetamine promotes non-exocytotic release of substrates in the presence of cocaine in an OCT3-dependent manner (Mayer et al., 2018) . Here we investigated a role for OCT3 in the mixed consumption of MDPV with mephedrone. Our results corroborate a potential contribution of OCT3 to the synergistic effects of MDPV and mephedrone when used in combination.
Materials and Methods
Radiotracer-flux experiments
Uptake experiments using [ 3 H]substrates of monoamine transporters were performed as described previously (Mayer et al., 2017) . Briefly, the murine (m) or human (h) isoforms of OCT3, hDAT, hNET and hSERT were expressed in human embryonic kidney by aspirating the tritiated substrate and washing the cells with ice-cold KHB. Finally, the cells were lysed in 1% sodium-dodecyl sulfate (SDS) and uptake of [ 3 H]substrate was determined by scintillation counting. Non-specific uptake was determined in presence of 10 µM paroxetine (hSERT), 10 µM mazindol (hDAT and hNET) or 10 µM decynium-22 (D22, mOCT3).
Transporter release experiments in superior cervical ganglia (SCGs) were performed as described in (Mayer et al., 2018) . SCG cultures were obtained following established protocols (Kristufek et al., 2002 , Salzer et al., 2014 . For release assays, SCGs were preloaded with [ 3 H]MPP + (0.1 µM in KHB, 30 minutes at 37°C). Subsequently, SCGs were placed into superfusion chambers (volume of 200 µL) and superfused with KHB (flow rate: 0.7 mL per minute) for 40 minutes to establish a stable baseline before the collection of 2-minute fractions was initiated. After three basal fractions, SCGs were superfused with D22 (0.1, 1 and 10 µM) or vehicle for three fractions before MDPV (10 µM) was added to the buffer for another three fractions. Finally, SCGs were exposed to mephedrone (10 µM, five fractions) and then lysed in 1% SDS to determine the total radioactivity. Radioactivity in the superfusates was determined by scintillation counting and the release of [ 3 H]MPP + was expressed as fractional rate, i.e. radioactivity released per 2-minute fraction is given as the percentage of total radioactivity present at the beginning of each fraction . To measure release of
HEK293 cells co-expressing NET and OCT3, the experiments were performed as described above for SCGs and as described in detail in , Mayer et al., 2017 .
Real-time measurements of fluorescent substrate accumulation and release
As described in detail in an earlier publication (Mayer et al., 2018) 
Drugs and Chemicals
[ 3 H]MPP + was obtained from ARC (St. Louis, MO, USA; specific activity: 80 Ci/mmol), mephedrone was from TOCRIS (Abingdon, United Kingdom) and MDPV was synthesized in its racemic form in the labratory of Nicholas V. Cozzi as described in (Baumann et al., 2013) . All other chemical used were obtained from Sigma Aldrich (St. Louis, MO, USA). 
Ethics declaration
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
Results
Mephedrone and MDPV inhibit DAT, NET and SERT-mediated substrate uptake but not that of OCT3
We first examined the ability of mephedrone and MDPV to inhibit uptake of substrates via OCT3. Figure 1 shows that neither mephedrone nor MDPV are potent inhibitors of inwardly directed transport of [ 3 H]MPP + via OCT3. Mephedrone has been reported to be a transported substrate for DAT, NET and SERT (Baumann et al., 2013 , Simmler et al., 2013 , Mayer et al., 2016 . Given the promiscuity of OCT3, substrates of DAT, NET and SERT may also serve as substrates of OCT3 (Koepsell et al., 2007) . We therefore investigated the effects of mephedrone on OCT3 in more detail. OCT3-expressing cells were superfused with the fluorescent substrate ASP + to assess OCT3 mediated-transport in real-time. Figure 2 illustrates that ASP + time-dependently accumulates in OCT3 expressing cells. Application of mephedrone (20 and 40 µM) had no direct effect on substrate accumulation in this assay. On the contrary, it is well documented that the OCT3-substrate MPP + and corticosterone inhibit uptake of ASP + via OCT3 (Massmann et al., 2014 , Mayer et al., 2018 . These data suggest that mephedrone does not act as either 
Mephedrone induces substrate efflux in the presence of MDPV in an OCT3-dependent manner in SCGs
The observation that OCT3 is MDPV-insensitive prompted us to speculate that combinations of MDPV and mephedrone may affect two different classes of monoamine transporters: i) high-affinity transporters of the SLC6-family, i.e. DAT, NET (and SERT) and ii) OCT3. We used SCGs as a model system, since these neurons richly express NET and OCT3 (Kristufek et al., 2002) . SCGs were pre-loaded with These findings suggest that there is an ongoing "leak" of intracellular substrate, which can most parsimoniously be explained by the presence of OCT3. Simple diffusion of [ 3 H]MPP + across the plasma membrane is not possible due to its permanent charge (Scholze et al., 2000) . In addition, this "leak" is further augmented in SCGs by mephedrone (Figure 4) .
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Discussion
The current study investigated potential contributions of OCT3 to the actions of the mixed abuse of MDPV and mephedrone, two of the most popular synthetic cathinones.
Earlier work by Cameron and colleagues (Cameron et al., 2013) , suggested that the combination of MDPV and mephedrone acts synergistically at monoamine transporters of the SLC6-family: first, mephedrone would induce reverse transport of dopamine via DAT. Subsequently; MDPV would prevent DAT-mediated re-uptake of previously released dopamine. However, at steady state, it seems plausible that MDPV would prevent mephedrone-induced reverse transport of dopamine by blocking its escape through DAT. Consistent with this notion, we observed that amphetamine-induced release of substrate via NET in hNET expressing HEK293 cells was effectively blocked in the presence of cocaine (Mayer et al., 2018) . Considering the high affinity of MDPV for DAT and NET (low nanomolar range) (see Figure 3 and (Baumann et al., 2013 , Simmler et al., 2013 ), it appears unlikely that mephedrone would induce carrier-mediated reverse transport of monoamines via DAT and NET in the presence of MDPV (given the assumption that both drugs are present within a similar concentration range).
Remarkably, however, we found that MDPV did not fully block mephedrone-induced OCT3 transports various endogenous and exogenous compounds, including monoamines. OCT3 is expressed throughout brain (Gasser et al., 2009) , including limbic regions (Gasser et al., 2009) and is expressed in neurons as well as in glial cells (Wu et al., 1998 , Kristufek et al., 2002 , Amphoux et al., 2006 , Gasser et al., 2006 , Vialou et al., 2008 , Mayer et al., 2018 . In contrast to DAT, NET and SERT, OCT3 is largely MDPV-and Mephedrone-insensitive (Figure 1 ). We found that mephedrone was still able to evoke release of pre-loaded (Baumann et al., 2013 , Simmler et al., 2013 . Importantly, and similar to the present findings, we described this kind of increase upon application of MDPV already in a previous publication (Baumann et al., 2013) . Furthermore, low concentrations of MDPV were associated with DAT-mediated release (Shekar et al., 2017) , whereas the molecular underpinnings underlying this observation remain to be identified. Non-transported inhibitors are not expected to elevate basal release of tritiated substrates ). Due to the permanent charge carried by MPP + , passive diffusion across cellular membranes precludes so-called "pseudo-efflux" events as an explanation (i.e. loss of substrate from the intracellular compartment that is unmasked when ongoing re-uptake is blocked by the presence of inhibitors (Scholze et al., 2000) ). Hence, we can only speculate about this phenomenon which is, nevertheless, only minor in magnitude.
In efforts to understand this apparent anomaly, we co-transfected HEK293 cells with NET and OCT3. Consistent with our finding of increased demonstrated earlier, reverse-transport rather than inhibition of inwardly-directed transport appears to be the primary mechanism driving the effects of amphetamines in vivo (Liechti et al., 2000) .
Given that psychostimulants are increasingly used as mixtures, consisting of cocaineand amphetamine-like drugs, OCT3 may serve as an explanation -in addition to the effects of these combinations on the pharmacokinetics of the abused drugs (Benturquia et al., 2018) -for the ability of these "combos" to produce a greater "high", as well as greater risk for deleterious effects associated with psychostimulant abuse.
Conclusion
The data at hand indicate that the combination of MDPV and mephedrone targets highaffinity and low-affinity monoamine transporters, which may underlie the synergistic 
